These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30359543)

  • 21. Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma.
    Shin IS; Jeon WY; Shin HK; Lee MY
    Int Immunopharmacol; 2013 Nov; 17(3):867-73. PubMed ID: 24126112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
    Cirstea D; Santo L; Hideshima T; Eda H; Mishima Y; Nemani N; Mahindra A; Yee A; Gorgun G; Hu Y; Ohguchi H; Suzuki R; Cottini F; Guichard SM; Anderson KC; Raje N
    Mol Cancer Ther; 2014 Nov; 13(11):2489-500. PubMed ID: 25172964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Montelukast: a review of its therapeutic potential in persistent asthma.
    Jarvis B; Markham A
    Drugs; 2000 Apr; 59(4):891-928. PubMed ID: 10804041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib-associated tumor lysis syndrome.
    Shely RN; Ratliff PD
    Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of treatment with montelukast on levels of serum interleukin-10, eosinophil cationic protein, blood eosinophil counts, and clinical parameters in children with asthma.
    Yüksel B; Aydemir C; Ustündag G; Eldeş N; Kutsal E; Can M; Demirtaş S; Tomaç N
    Turk J Pediatr; 2009; 51(5):460-5. PubMed ID: 20112601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of montelukast on polymorphonuclear leukocyte functions in asthmatic patients.
    Gürer US; Büyüköztürk S; Palandüz S; Gürbüz B; Cevikbaş A
    Int Immunopharmacol; 2003 Sep; 3(9):1257-60. PubMed ID: 12890423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
    Leff JA; Busse WW; Pearlman D; Bronsky EA; Kemp J; Hendeles L; Dockhorn R; Kundu S; Zhang J; Seidenberg BC; Reiss TF
    N Engl J Med; 1998 Jul; 339(3):147-52. PubMed ID: 9664090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of exercise training and montelukast in children with mild asthma.
    Bonsignore MR; La Grutta S; Cibella F; Scichilone N; Cuttitta G; Interrante A; Marchese M; Veca M; Virzi' M; Bonanno A; Profita M; Morici G
    Med Sci Sports Exerc; 2008 Mar; 40(3):405-12. PubMed ID: 18379200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on the use of montelukast in pediatric asthma.
    Capristo C; Rigotti E; Boner AL
    Allergy Asthma Proc; 2006; 27(4):312-8. PubMed ID: 16948343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
    Bringhen S; Milan A; D'Agostino M; Ferri C; Wäsch R; Gay F; Larocca A; Offidani M; Zweegman S; Terpos E; Goldschmidt H; Cavo M; Ludwig H; Driessen C; Auner HW; Caers J; Gramatzki M; Dimopoulos MA; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M
    J Intern Med; 2019 Jul; 286(1):63-74. PubMed ID: 30725503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation.
    Nadeem A; Obiefuna PC; Wilson CN; Mustafa SJ
    Eur J Pharmacol; 2006 Dec; 551(1-3):116-24. PubMed ID: 17027749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of montelukast for recurrent wheeze in preschool children.
    Hussein HR; Gupta A; Broughton S; Ruiz G; Brathwaite N; Bossley CJ
    Eur J Pediatr; 2017 Jul; 176(7):963-969. PubMed ID: 28567533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials.
    Chen R; Chen B; Zhang X; Gao C
    Discov Med; 2016 Oct; 22(121):189-199. PubMed ID: 27875670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose desloratadine and montelukast and allergen-induced late airway responses.
    Davis BE; Illamperuma C; Gauvreau GM; Watson RM; O'Byrne PM; Deschesnes F; Boulet LP; Cockcroft DW
    Eur Respir J; 2009 Jun; 33(6):1302-8. PubMed ID: 19164343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
    Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
    Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.